Over 20’000 Company Profiles now available in the new Version of Biotechgate
The new version of Biotechgate, the global Biotech and Life Sciences Database, provides the user with a new interface for accessing over 20’000 company profiles, financing rounds, detailed medical technology and biotechnology products. The database provides different levels of access, from a free subscription to monthly and annual subscriptions starting at EUR 125 per month. Even a free subscription allows users to see how many products, companies or financing rounds fit their search criteria. The paid subscription provides a whole lot more information and search options.
Furthermore, Biotechgate recently hit the magic number of 20’000 worldwide company profiles. Each profile is either complemented and checked by the company itself or up-date by the Biotechgate team to ensure high data quality. The addition of new partners, such as One Nucleus, APIM – the Lille Metropole Development Agency and Assobiotec - the Italian Association for the Development of Biotechnology, helped to reach this number.
Passing the 20’000 company mark is an important milestone and showcases the global coverage of Biotechgate. The database began in 2003 as a local country resource for Switzerland, mapping the life sciences industry focusing on Biotechnology and Medical Technology. Subsequently, new countries were added and the database grew rapidly to a global platform, supporting institutions like the European Commission, EBD Group, NatureJobs, and spanning from the US (Biocom San Diego, Maryland), Canada (BIOTECanada) to Europe including the UK (One Nucleus), Scandinavia (Medicon Valley, Invest in Skane, Copenhagen Capacity), Germany (BIO.NRW), Netherlands (Life Sciences Health), France (APIM), Switzerland (Basel Area/Biovalley, Greater Zurich Area, Swiss Biotech Association, Swiss Stock Exchange SIX, BioAlps, BioteCHnet), Italy (Assobiotec), across Eastern Europe (14allbio.eu) all the way to India and South Korea (SGI).
"We are very happy to launch this new version and make the database even more accessible. Our key focus is on private, small companies, often not on the radar screen. Through our unique collaboration with local partners such as biotech networks and association, as well as economic development agencies, we have built the database bottom-up and thus can offer data that others do not have.” said Dr. Patrik Frei, CEO of Venture Valuation, the provider of Biotechgate.
For further information: Dr. Patrik Frei, CEO, Biotechgate c/o Venture Valuation Inc, Switzerland, +41 (43) 321 8660, p.frei (at) venturevaluation.com
About us: Venture Valuation (www.venturevaluation.com)
Venture Valuation specializes in independent, third party assessment, valuation and monitoring of emerging high growth companies in industries such as biotechnology, med-tech and high-tech. Services are provided in the form of independent Valuation Reports to entrepreneurs (seed to pre-IPO) and investors. With offices in Switzerland, Germany, Canada and Asia, Venture Valuation has an experienced team of scientists and business professionals with expertise in finance, biotechnology and pharmaceutical.
About us: Biotechgate (www.biotechgate.com)
The Biotechgate Database is property of Venture Valuation AG, Switzerland. Biotechgate is a global Life Sciences Database containing over 20’000 company profiles and providing the user with information on available licensing products, financing rounds, key management, technology platforms. It also contains a licensing deals database, all with financial information on the specific deal. The database supports its user by identifying companies matching certain criteria (development face, financing rounds, valuation, available product for out-licensing and many more).
Venture Valuation AG
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Over 20’000 Company Profiles now available in the new Version of Biotechgate here
News-ID: 166344 • Views: 1934
More Releases for Biotech
Global Acetaminophen (Paracetamol) Market 2020 | Genesis Biotech, M.M. Pharma, A …
The Global Acetaminophen (Paracetamol) Market research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry validated market data. It also contains projections using a suitable set of assumptions and methodologies. The study provides company profiling, product picture and specifications, sales, market share and contact information of key manufacturers of Global Acetaminophen (Paracetamol) Market.The Key manufactures involved in this market
Global Phycobiliprotein Market 2017 Norland Biotech, Algapharma Biotech, Phyco-B …
Global Phycobiliprotein Market Report 2017 Phycobiliprotein industrial chain, this report mainly elaborate the definition, types, applications and major players of Phycobiliprotein market in details. Deep analysis about market status (2012-2017), enterprise competition pattern, advantages and disadvantages of enterprise Products, industry development trends (2017-2022), regional industrial layout characteristics and macroeconomic policies, industrial policy has also be included. From raw materials to downstream buyers of this industry will be analyzed scientifically, the
GLOBAL PHYCOBILIPROTEIN MARKET- DAINIPPON INK AND CHEMICALS, PHYCO-BIOTECH 2 COL …
Global Industry Study Evaluate on Phycobiliprotein Market by Type Manufacturers Regions and Application Forecast up to 2022 The scope of the Phycobiliprotein Report: This report primarily focuses on Phycobiliprotein in the global market. This report generally covers Phycobiliprotein market in North America Phycobiliprotein market in Asia-Pacific Phycobiliprotein market in Europe Phycobiliprotein market in Latin America Middle as well as Africa. This report partitions the Phycobiliprotein market based on Application Manufacturers Countries as
Harver Group Targets BioTech Bull
Synta Pharmaceuticals has a bullish outlook for Q3-Q4; insider buying indicates the company will be releasing positive research results and see a gain in returns. Jul. 24, 2013 - CHUO-KU, Japan -- Due to the huge increase in staff and board members buying stock in Synta Pharmaceuticals, and the successful trials of Synta Pharmaceuticals latest cancer drug Ganetespib, Pharmaceutical Analysts at Harver Group are now strongly recommending the stock as a
Biotech API Surging Worldwide
According to a new research report by RNCOS, entitled “Global Biotech API Market Analysis”, geographies across the world are showing insurgent growth in the biotech API Industry. The US occupied more than half of the share in the global market in 2011, and is the largest producer of biotech APIs. Western European countries occupy around 15% share globally among which, the UK is the largest producer of biotechnology-based APIs. The
Biotech APIs Showing Insurgent Growth
According to a new research report by RNCOS entitled, “Global Biotech API Market Analysis”, the rapidly growing and innovating biopharmaceuticals and biotechnology industry as a whole is putting the biotech API industry into charts of insurgent growth. Research Analysis & Highlights The report, “Global Biotech API Market Analysis”, spread over 55 pages, provides an in-depth research and rational analysis of the current and expected status of the biotech API industry across the